Threshold of main pancreatic duct for malignancy in intraductal papillary mucinous neoplasm at head-neck and body-tail.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Carcinoma, Pancreatic Ductal*/diagnostic imaging ; Carcinoma, Pancreatic Ductal*/pathology ; Pancreatic Neoplasms*/diagnostic imaging ; Pancreatic Neoplasms*/pathology; Humans ; Pancreatic Ducts/diagnostic imaging ; Pancreatic Ducts/pathology ; Head ; Tomography, X-Ray Computed

Background: Main pancreatic duct (MPD) dilation is a high-risk stigmata/worrisome feature of malignancy in intraductal papillary mucinous neoplasms (IPMNs). The threshold of MPD diameter in predicting malignancy may be related to the lesion location. This study aimed to separately identify the thresholds of MPD for malignancy of IPMNs separately for the head-neck and body-tail.
Materials and Methods: A total of 185 patients with pathologically confirmed IPMNs were included. Patient demographic information, clinical data, and pathological features were obtained from the medical records. Those IPMNs with high-grade dysplasia or with associated invasive carcinoma were considered as malignant tumor. Radiological data including lesion location, tumor size, diameter of the MPD, mural nodule, and IPMN types (main duct, MD; branch duct, BD; and mixed type, MT), were collected on computed tomography or magnetic resonance imaging. Serum carbohydrate antigen 19-9 levels, serum carcinoembryonic antigen levels, and the medical history of diabetes mellitus, chronic cholecystitis, and pancreatitis were also collected.
Results: Malignant IPMNs were detected in 31.6% of 117 patients with lesions in the pancreatic head-neck and 20.9% of 67 patients with lesions in the pancreatic body-tail. In MPD-involved IPMNs, malignancy was observed in 54.1% of patients with lesions in the pancreatic head-neck and 30.8% of patients with lesions in the pancreatic body-tail (p < 0.05). The cutoff value of MPD diameter for malignancy was 6.5 mm for lesions in the head-neck and 7.7 mm for lesions in the body-tail in all type of IPMNs. In MPD-involved IPMNs, the threshold was 8.2 mm for lesion in pancreatic head-neck and 7.7 mm for lesions in the body-tail. Multivariate analysis confirmed that MPD diameter ≥ 6.5 mm (pancreatic head-neck) and MPD diameter ≥ 7.7 mm (pancreatic body-tail) were independent predictors of malignancy (p < 0.05). Similar results were observed in MPD-involved IPMNs using 8.2 mm as a threshold.
Conclusion: The thresholds of the dilated MPD may be associated with IPMNs locations. Thresholds of 6.5 mm for lesions in the head-neck and 7.7 mm for lesions in the body-tail were observed. For MPD-involved IPMNs alone, threshold for lesions in the head-neck was close to that in the body-tail.
(© 2022. The Author(s).)

J Gastroenterol. 2020 Jan;55(1):86-99. (PMID: 31463655)
Surgery. 2014 Sep;156(3):611-21. (PMID: 25081232)
HPB (Oxford). 2019 Apr;21(4):482-488. (PMID: 30361110)
Ann Surg. 2014 Oct;260(4):680-8; discussion 688-90. (PMID: 25203885)
Clin Gastroenterol Hepatol. 2022 Feb;20(2):272-275. (PMID: 33581356)
Gastrointest Endosc. 2020 Jul;92(1):1-8.e3. (PMID: 32014422)
JAMA Surg. 2017 Jan 18;152(1):e163349. (PMID: 27829085)
Langenbecks Arch Surg. 2019 Feb;404(1):31-37. (PMID: 30612152)
Pancreatology. 2020 Jun;20(4):729-735. (PMID: 32332003)
Endoscopy. 2022 Jul 08;:. (PMID: 35451041)
HPB (Oxford). 2009 Dec;11(8):664-70. (PMID: 20495634)
World J Surg. 2015 Aug;39(8):2006-13. (PMID: 25894399)
Gastrointest Endosc. 2014 Apr;79(4):623-9. (PMID: 24094923)
Clin Gastroenterol Hepatol. 2022 Feb;20(2):390-399.e7. (PMID: 33385536)
Pancreatology. 2017 Sep - Oct;17(5):738-753. (PMID: 28735806)
BMC Gastroenterol. 2020 Dec 9;20(1):413. (PMID: 33297971)
Gastrointest Endosc. 2021 Nov;94(5):881-889.e5. (PMID: 34217751)
Front Oncol. 2021 Jun 03;11:681961. (PMID: 34178672)
Pancreas. 2016 Oct;45(9):1227-32. (PMID: 27171512)
Endosc Ultrasound. 2015 Oct-Dec;4(4):324-9. (PMID: 26643701)
Pancreas. 2020 Apr;49(4):552-560. (PMID: 32282769)
Gastrointest Endosc. 2022 Jun;95(6):1067-1077.e15. (PMID: 35124072)
Ann Surg. 2015 Nov;262(5):875-80; discussion 880-1. (PMID: 26583679)
Ann Surg. 2020 Dec;272(6):1118-1124. (PMID: 30672797)

Keywords: Dysplasia; Intraductal papillary mucinous neoplasms; Invasive carcinoma; Main pancreatic duct; Malignancy

Date Created: 20221119 Date Completed: 20221122 Latest Revision: 20221123

20250114

PMC9675150

10.1186/s12876-022-02577-3

36402960